Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk Unveils Strategy For Dominating Diabetes Market In China

This article was originally published in PharmAsia News

Executive Summary

Novo Nordisk has carved out a dominant position in China's diabetic drug market despite launching only one oral hypoglycemic agent and insulin thanks to its 20-year presence in the country that allows the establishment of an extensive sales network. Its revenue is evenly split between key cities and periphery markets. The company's strategy is to actively conduct health education on diabetes in two areas, namely, mainstream patient education and physician training in communities. In addition, Novo Nordisk expects to make an official announcement this October about its plans to set up a plant in Tianjin that will supply products to China and more than 200 countries worldwide. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts